Skip to main content

8 Result(s)

within Jasmin Bahlo Remove this filter

and

  1. Article

    Open Access

    Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial

    We report a randomized prospective phase 3 study (CLL7), designed to evaluate the efficacy of fludarabine, cyclophosphamide, and rituximab (FCR) in patients with an early-stage high-risk chronic lymphocytic le...

    Carmen D. Herling, Florence Cymbalista, Carolin Groß-Ophoff-Müller… in Leukemia (2020)

    Download PDF (841 KB) View Article

  2. No Access

    Article

    Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group

    The heterogeneity of early stage CLL challenges prognostication, and refinement of prognostic indices for risk-adapted management in this population is essential. The aim of the multicenter, prospective CLL1 t...

    Manuela A. Hoechstetter, Raymonde Busch, Barbara Eichhorst, Andreas Bühler… in Leukemia (2020)

  3. Article

    Open Access

    Machine learning can identify newly diagnosed patients with CLL at high risk of infection

    Infections have become the major cause of morbidity and mortality among patients with chronic lymphocytic leukemia (CLL) due to immune dysfunction and cytotoxic CLL treatment. Yet, predictive models for infect...

    Rudi Agius, Christian Brieghel, Michael A. Andersen… in Nature Communications (2020)

    Download PDF (3120 KB) View Article

  4. No Access

    Article

    Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL

    Chronic lymphocytic leukemia (CLL) cells depend on microenvironmental non-malignant cells for survival. We compared the transcriptomes of primary CLL cells cocultured or not with protective bone marrow stromal...

    Deyan Yordanov Yosifov, Irina Idler, Nupur Bhattacharya, Michaela Reichenzeller… in Leukemia (2020)

  5. No Access

    Article

    Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia

    Telomere length in chronic lymphocytic leukemia (CLL) has been shown to be of prognostic importance, but the analyses have largely been executed on heterogeneous patient cohorts outside of clinical trials. In ...

    Billy Michael Chelliah Jebaraj, Eugen Tausch, Dan A. Landau, Jasmin Bahlo… in Leukemia (2019)

  6. No Access

    Article

    CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia

    Obinutuzumab (GA101) and ibrutinib show excellent efficacy for treatment of chronic lymphocytic leukemia (CLL). Preclinical investigations and a complementary safety profile were in support of testing their co...

    Julia von Tresckow, Paula Cramer, Jasmin Bahlo, Sandra Robrecht… in Leukemia (2019)

  7. Article

    Open Access

    Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia

    Chronic lymphocytic leukemia (CLL) remains an incurable disease. Two recurrent cytogenetic aberrations, namely del(17p), affecting TP53, and del(11q), affecting ATM, are associated with resistance against genotox...

    Gero Knittel, Tim Rehkämper, Darya Korovkina, Paul Liedgens… in Nature Communications (2017)

    Download PDF (3484 KB) View Article

  8. No Access

    Article

    Mutations driving CLL and their evolution in progression and relapse

    Which genetic alterations drive tumorigenesis and how they evolve over the course of disease and therapy are central questions in cancer biology. Here we identify 44 recurrently mutated genes and 11 recurrent ...

    Dan A. Landau, Eugen Tausch, Amaro N. Taylor-Weiner, Chip Stewart… in Nature (2015)